GlassScriptPhysician profile
Ann George
NPI 1568819795
$8,091.01
in general payments reported to CMS, 2019-2025
31 companies · $2,326 in 2025
The $2,326 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.27 · 2020: $10.97 · 2021: $62.86 · 2022: $1,522 · 2023: $1,210 · 2024: $2,888 · 2025: $2,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,126 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,126.31 |
| Education | $297.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,195.97 | 2022-2025 | |
| Janssen Biotech, INC. | $1,189.44 | 2022-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $1,014.31 | 2022-2025 | Enbrel, Tavneos, Otezla |
| Novartis Pharmaceuticals Corporation | $576.85 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $493.79 | 2022-2025 | Saphnelo |
| Ucb, INC. | $489.71 | 2022-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $349.60 | 2023-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $301.17 | 2022-2025 | Orencia |
| Pfizer INC. | $290.75 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $240.19 | 2022-2025 | Lupkynis |
| Radius Health, INC. | $104.61 | 2024-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.02 | 2021-2024 | Cyltezo |
| Mallinckrodt Hospital Products INC. | $87.06 | 2022-2025 | Acthar |
| Sobi, INC | $81.89 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $64.73 | 2022-2025 | Strensiq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $55.24 | 2023-2025 | Idacio |
| Janssen Pharmaceuticals, INC | $54.86 | 2022 | |
| Gilead Sciences, INC. | $53.46 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $51.70 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $45.12 | 2024 | Arcalyst |
| Genentech USA, INC. | $44.20 | 2024-2025 | Gazyva, Actemra |
| Ultragenyx Pharmaceutical INC. | $41.11 | 2023-2024 | Crysvita |
| Horizon Therapeutics Plc | $26.00 | 2023 | |
| Viiv Healthcare Company | $23.72 | 2019 | |
| Kyowa Kirin, INC. | $21.35 | 2025 | |
| Ani Pharmaceuticals, INC. | $21.11 | 2023 | Purified Cortrophin Gel |
| Sun Pharmaceutical Industries INC. | $19.07 | 2022 | |
| Invivyd INC | $18.19 | 2025 | Pemgarda |
| Shire North American Group INC | $18.18 | 2019 | |
| Genzyme Corporation | $15.90 | 2024 | |
| Glaxosmithkline, LLC. | $13.71 | 2024 | Benlysta, Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.